UPC Shuts Down Tumor Drug Feud After EPO Voids Patent
The Unified Patent Court has called time on Neurocrine Biosciences Inc.'s challenge to Spruce Biosciences Inc.'s tumor drug patent after the European Patent Office revoked the intellectual property at the center...To view the full article, register now.
Already a subscriber? Click here to view full article